Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01168973
Registration number
NCT01168973
Ethics application status
Date submitted
16/07/2010
Date registered
23/07/2010
Date last updated
25/09/2019
Titles & IDs
Public title
A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy
Query!
Scientific title
A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy
Query!
Secondary ID [1]
0
0
I4T-MC-JVBA
Query!
Secondary ID [2]
0
0
13852
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Non-Small Cell Lung Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Mesothelioma
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Cancer
0
0
0
0
Query!
Lung - Small cell
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - Ramucirumab
Treatment: Drugs - Placebo (for Ramucirumab)
Treatment: Drugs - Docetaxel
Experimental: Ramucirumab + Docetaxel -
Placebo Comparator: Placebo + Docetaxel -
Other interventions: Ramucirumab
10 milligrams per kilogram (mg/kg) administered intravenously (IV) on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
Treatment: Drugs: Placebo (for Ramucirumab)
Administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
Treatment: Drugs: Docetaxel
75 milligrams per square meter (mg/m^2) (60 mg/m^2 for the countries of Korea and Taiwan only with protocol amendment dated 22 May 2012) administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
Query!
Intervention code [1]
0
0
Other interventions
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival
Query!
Assessment method [1]
0
0
Overall survival was the time from randomization until the date of death from any cause. Participants who were alive at the end of the follow-up period (or lost to follow-up) were censored on the last date the participant was known to be alive.
Query!
Timepoint [1]
0
0
Randomization to date of death from any cause (up to 34 months)
Query!
Secondary outcome [1]
0
0
Progression-Free Survival (PFS) Time
Query!
Assessment method [1]
0
0
PFS time was the time from randomization until the date of objectively determined progressive disease (PD) or death due to any cause, whichever occurred first. According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), PD was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the 20% relative increase, the sum must have also demonstrated an absolute increase of at least 5 millimeters (mm). The appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions was also considered progression. Participants without objectively determined PD who were alive at the end of the follow-up period (or lost to follow-up) were censored on the date of the participant's last complete radiographic tumor assessment; if no baseline or post-baseline radiologic assessment was available, the participant was censored at the date of randomization.
Query!
Timepoint [1]
0
0
Randomization to measured PD or date of death from any cause (up to 29 months)
Query!
Secondary outcome [2]
0
0
Percentage of Participants Achieving an Objective Response (Objective Response Rate)
Query!
Assessment method [2]
0
0
Participants achieved an objective response if they had a best overall response of partial response (PR) or complete response (CR). According to RECIST v1.1, PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter; CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to <10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels [if tumor markers were initially above the upper limit of normal (ULN)]. The percentage of participants who achieved an objective response=(number of participants with CR or PR)/(number of participants assessed)*100.
Query!
Timepoint [2]
0
0
Baseline to measured PD (up to 29 months)
Query!
Secondary outcome [3]
0
0
Percentage of Participants Achieving Disease Control (Disease Control Rate)
Query!
Assessment method [3]
0
0
Participants achieved disease control if they had a best overall response of PR, CR or stable disease (SD). According to RECIST v1.1, PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter; CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to <10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels (if tumor markers were initially above the ULN). SD was neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD, taking as reference the smallest sum diameter since treatment started. The percentage of participants who achieved disease control=(number of participants with CR, PR, or SD)/(number of participants assessed)*100.
Query!
Timepoint [3]
0
0
Baseline to measured PD (up to 29 months)
Query!
Secondary outcome [4]
0
0
Maximum Improvement on Lung Cancer Symptom Scale (LCSS)
Query!
Assessment method [4]
0
0
The LCSS consisted of 9 items: 6 items focused on lung cancer symptoms [loss of appetite, fatigue, cough, dyspnea (shortness of breath), hemoptysis (blood in sputum), and pain] and 3 items were global items (symptom distress, interference with activity level, and global quality of life). Participant responses to each item were measured using visual analogue scales (VAS) with 100-mm lines. A higher score for any item represented a higher level of symptoms/problems. The Average Symptom Burden Index (ASBI) was the mean of the 6 symptom items of the LCSS, and the Total LCSS was the mean of all 9 LCSS items. ASBI and Total LCSS were not computed for a participant if he/she had 1 or more missing values for the 6 and 9 items, respectively. Maximum improvement in LCSS scores, ASBI, and Total LCSS score was the largest decrease from baseline for each variable, which was the smallest (most negative or smallest positive) non-missing value among all change from baseline values for each variable.
Query!
Timepoint [4]
0
0
Baseline, Day 21 of each cycle, and 30 days following last infusion (up to Cycle 38, 21 days/cycle)
Query!
Secondary outcome [5]
0
0
Change From Baseline to 30-Day Follow-Up Visit on European Quality of Life Questionnaire-5 Dimension (EQ-5D) Health State Scores
Query!
Assessment method [5]
0
0
The EQ-5D is a quality-of-life instrument that consists of 2 parts. The first part (Health State Index score) allowed participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a scale from 1 to 3 (no problem, some problems, and extreme problems, respectively). These combinations of attributes were converted into a weighted Health State Index score according to a United Kingdom population-based algorithm; the possible values for the Health State Index score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension). The second part of the EQ-5D was a VAS that allowed participants to rate their present health condition. Possible EQ-5D VAS scores ranged from 0 (worst imaginable health state) to 100 (best imaginable health state).
Query!
Timepoint [5]
0
0
Baseline, 30 days following last infusion (up to Cycle 38, 21 days/cycle)
Query!
Secondary outcome [6]
0
0
Maximum and Minimum Serum Concentrations (Cmax and Cmin) of Ramucirumab
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Prior to infusion and 1 hour following infusion for 4 and 8 (cycles 3 and 5 at 21 days/cycle)
Query!
Secondary outcome [7]
0
0
Number of Participants With Anti-Ramucirumab Antibodies
Query!
Assessment method [7]
0
0
The number of participants who had treatment-emergent or follow-up emergent anti-drug antibodies (ADA) is reported. Participants with treatment-emergent ADA were defined as participants who had any sample from baseline through Cycle 5 pre-infusion that was a 4-fold increase (2 dilution increase) in immunogenicity titer over the baseline titer, or participants who tested negative at baseline and positive post-baseline (at titer of =1:20). Participants with follow-up emergent ADA were defined as participants who had any sample during 30 days post last infusion that was a 4-fold increase (2 dilution increase) in immunogenicity titer over the baseline titer.
Query!
Timepoint [7]
0
0
Baseline, prior to infusion for week 4 and 8 (cycles 3 and 5), and 30 days following last infusion (up to Cycle 38, 21 days/cycle)
Query!
Eligibility
Key inclusion criteria
- Disease progression during or after one prior first-line platinum-based chemotherapy
with or without maintenance therapy
- Prior bevacizumab as first-line and/or maintenance therapy is allowed
- Signed informed consent
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Histologically or cytologically confirmed NSCLC
- Stage IV NSCLC disease
- Participants have measurable or nonmeasurable disease
- Adequate organ function, defined as:
- Total bilirubin less than or equal to Upper Limit of Normal (ULN),
- Aspartate Aminotransferase (AST) and Alanine Aminotransaminase (ALT) less than or
equal to 2.5 x ULN, or less than or equal to 5 x ULN if the transferase elevation
is due to liver metastases,
- Serum creatinine less than or equal to 1.5 x ULN or calculated creatinine
clearance greater than or equal to 50 milliliters per minute (ml/min) (per the
Cockcroft-Gault formula or equivalent and/or 24-hour urine collection),
- Absolute Neutrophil Count (ANC) greater than or equal to 1.5 x 10^3/microliters
(µL), hemoglobin greater than or equal to 10.0 grams/deciliter (g/dL), and
platelets greater than or equal to 100 x 10^3/µL,
- Adequate coagulation function as defined by International Normalized Ratio (INR)
less than or equal to 1.5, or prothrombin time and partial thromboplastin time
less than or equal to 1.5 x ULN.
- The participant does not have cirrhosis at a level of Child-Pugh B (or worse) or
cirrhosis (any degree) and a history of hepatic encephalopathy or clinically
meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is
defined as ascites resulting from cirrhosis and requiring ongoing treatment with
diuretics and/or paracentesis.
- Urinary protein is less than or equal to 1+ on dipstick or routine urinalysis. If
urine dipstick or routine analysis indicates proteinuria greater than or equal to 2+,
a 24-hour urine must be collected and must demonstrate less than 1000 milligrams (mg)
of protein.
- Participants of reproductive potential (both sexes) must agree to use reliable method
of birth control (hormonal or barrier methods) during the study period and at least 12
weeks after the last dose of study therapy
- Life expectancy of greater than or equal to 3 months
- Prior radiation therapy is allowed if: In the case of chest radiotherapy at least 28
days have elapsed from the completion of radiation treatment prior to randomization;
In the case of focal or palliative radiation treatment at least 7 days have elapsed
from last radiation treatment prior to randomization (and provided that 25% or less of
total bone marrow had been irradiated); In the case of Central Nervous System (CNS)
radiation at least 14 days have elapsed from the completion of radiation treatment
prior to randomization
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Disease progression on more than 1 prior chemotherapy regimens
- Participants whose only prior treatment was a tyrosine kinase inhibitor
- The participant's tumor wholly or partially contains small cell lung cancer
- Major surgery within 28 days prior to randomization, or subcutaneous venous access
device placement within 7 days prior to randomization. Postoperative bleeding
complications or wound complications from a surgical procedure performed in the last 2
months.
- Concurrent treatment with other anticancer therapy, including other chemotherapy,
immunotherapy, hormonal therapy, chemoembolization, or targeted therapy
- Last dose of bevacizumab must be at least 28 days from time of randomization
- Last dose of cytotoxic chemotherapy must be at least 14 days from time of
randomization
- The participant has untreated CNS metastases. Participants with treated brain
metastases are eligible if they are clinically stable with regard to neurologic
function, off steroids after cranial irradiation ending at least 2 weeks prior to
randomization, or after surgical resection performed at least 28 days prior to
randomization. No evidence of Grade greater than or equal to 1 CNS hemorrhage based on
pretreatment Magnetic Resonance Imaging (MRI) or IV contrast Computed Tomography (CT)
scan.
- Radiologically documented evidence of major blood vessel invasion or encasement by
cancer
- Radiographic evidence of intratumor cavitation
- History of uncontrolled hereditary or acquired thrombotic disorder
- Chronic therapy with nonsteroidal anti-inflammatory drug (NSAIDs) or other
antiplatelet agents; Aspirin use at doses up to 325 milligrams per day (mg/day) is
permitted
- History of gross hemoptysis (defined as bright red blood or greater than or equal to
1/2 teaspoon) within 2 months prior to randomization
- Clinically relevant congestive heart failure [New York Heart Association (NYHA II-IV)]
or symptomatic or poorly controlled cardiac arrhythmia
- Any arterial thrombotic event, including myocardial infarction, unstable angina,
cerebrovascular accident, or transient ischemic attack, within 6 months prior to
randomization
- Uncontrolled arterial hypertension greater than or equal to 150 / greater than or
equal to 90 millimeters of mercury (mm Hg) despite standard medical management
- Serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to
randomization
- Significant bleeding disorders, vasculitis, or Grade 3/4 gastrointestinal bleeding
within 3 months prior to randomization
- Gastrointestinal (GI) perforation and/or fistulae within 6 months prior to
randomization
- Bowel obstruction, history or presence of inflammatory enteropathy or extensive
intestinal resection Crohn's disease, ulcerative colitis, or chronic diarrhea
- Peripheral neuropathy greater than or equal to Grade 2 [National Cancer Institute
Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.02]
- Serious illness or medical condition(s) including, but not limited to: Human
immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome
(AIDS)-related illness; Active or uncontrolled clinically serious infection; Severe
acute or chronic medical or psychiatric condition or laboratory abnormality that may
increase the risk associated with study participation or study drug administration
- Known allergy or hypersensitivity reaction to any of the treatment components
- The participant is pregnant or breastfeeding
- Current or recent (within 28 days prior to randomization) treatment with an
investigational drug or device that has not received regulatory approval for any
indication at the time of randomization, or participation in another interventional
clinical trial
- Prior therapy with docetaxel
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/12/2010
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/08/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1253
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Indiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Iowa
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kansas
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Kentucky
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Louisiana
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Maryland
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Massachusetts
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Michigan
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Minnesota
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Missouri
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Montana
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Nevada
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
New Hampshire
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
New Mexico
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
New York
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
North Carolina
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
North Dakota
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Ohio
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Oklahoma
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Pennsylvania
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
South Carolina
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
South Dakota
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Tennessee
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Texas
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Virginia
Query!
Country [34]
0
0
United States of America
Query!
State/province [34]
0
0
Washington
Query!
Country [35]
0
0
United States of America
Query!
State/province [35]
0
0
Wisconsin
Query!
Country [36]
0
0
Argentina
Query!
State/province [36]
0
0
Buenos Aires
Query!
Country [37]
0
0
Argentina
Query!
State/province [37]
0
0
Córdoba
Query!
Country [38]
0
0
Argentina
Query!
State/province [38]
0
0
La Rioja
Query!
Country [39]
0
0
Argentina
Query!
State/province [39]
0
0
Rosario
Query!
Country [40]
0
0
Argentina
Query!
State/province [40]
0
0
Tucumain
Query!
Country [41]
0
0
Argentina
Query!
State/province [41]
0
0
Viedma
Query!
Country [42]
0
0
Austria
Query!
State/province [42]
0
0
Graz
Query!
Country [43]
0
0
Austria
Query!
State/province [43]
0
0
Grimmenstein
Query!
Country [44]
0
0
Austria
Query!
State/province [44]
0
0
Vienna
Query!
Country [45]
0
0
Austria
Query!
State/province [45]
0
0
Wels
Query!
Country [46]
0
0
Brazil
Query!
State/province [46]
0
0
Barretos
Query!
Country [47]
0
0
Brazil
Query!
State/province [47]
0
0
Belo Horizonte
Query!
Country [48]
0
0
Brazil
Query!
State/province [48]
0
0
Goiania
Query!
Country [49]
0
0
Brazil
Query!
State/province [49]
0
0
Porto Alegre
Query!
Country [50]
0
0
Brazil
Query!
State/province [50]
0
0
São Paulo
Query!
Country [51]
0
0
Canada
Query!
State/province [51]
0
0
Alberta
Query!
Country [52]
0
0
Canada
Query!
State/province [52]
0
0
New Brunswick
Query!
Country [53]
0
0
Canada
Query!
State/province [53]
0
0
Quebec
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Grenoble
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Lille
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Lyon
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Nice
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Strasbourg
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Toulouse
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
Vandoeuvre Les Nancy
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Augsburg
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Bad Soden
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Bielefeld
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Dresden
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Frankfurt
Query!
Country [66]
0
0
Germany
Query!
State/province [66]
0
0
Gerlingen
Query!
Country [67]
0
0
Germany
Query!
State/province [67]
0
0
Großhansdorf
Query!
Country [68]
0
0
Germany
Query!
State/province [68]
0
0
Halle
Query!
Country [69]
0
0
Germany
Query!
State/province [69]
0
0
Heidelberg
Query!
Country [70]
0
0
Germany
Query!
State/province [70]
0
0
Immenhausen
Query!
Country [71]
0
0
Germany
Query!
State/province [71]
0
0
Oldenburg
Query!
Country [72]
0
0
Germany
Query!
State/province [72]
0
0
Ulm
Query!
Country [73]
0
0
Germany
Query!
State/province [73]
0
0
Villingen-Schwenningen
Query!
Country [74]
0
0
Greece
Query!
State/province [74]
0
0
Athens
Query!
Country [75]
0
0
Greece
Query!
State/province [75]
0
0
Chania
Query!
Country [76]
0
0
Greece
Query!
State/province [76]
0
0
Kifissia
Query!
Country [77]
0
0
Greece
Query!
State/province [77]
0
0
Patras
Query!
Country [78]
0
0
Hungary
Query!
State/province [78]
0
0
Budapest
Query!
Country [79]
0
0
Hungary
Query!
State/province [79]
0
0
Gyula
Query!
Country [80]
0
0
Hungary
Query!
State/province [80]
0
0
Matrahaza
Query!
Country [81]
0
0
Hungary
Query!
State/province [81]
0
0
Nyiregyhaza
Query!
Country [82]
0
0
Hungary
Query!
State/province [82]
0
0
Pécs
Query!
Country [83]
0
0
Hungary
Query!
State/province [83]
0
0
Szekesfehervar
Query!
Country [84]
0
0
India
Query!
State/province [84]
0
0
Bangalore
Query!
Country [85]
0
0
India
Query!
State/province [85]
0
0
Cuttack
Query!
Country [86]
0
0
India
Query!
State/province [86]
0
0
Delhi
Query!
Country [87]
0
0
India
Query!
State/province [87]
0
0
Jaipur
Query!
Country [88]
0
0
India
Query!
State/province [88]
0
0
Kochin
Query!
Country [89]
0
0
India
Query!
State/province [89]
0
0
Madurai
Query!
Country [90]
0
0
India
Query!
State/province [90]
0
0
Mumbai
Query!
Country [91]
0
0
India
Query!
State/province [91]
0
0
Pune
Query!
Country [92]
0
0
India
Query!
State/province [92]
0
0
Trivandrum
Query!
Country [93]
0
0
Israel
Query!
State/province [93]
0
0
Haifa
Query!
Country [94]
0
0
Israel
Query!
State/province [94]
0
0
Jerusalem
Query!
Country [95]
0
0
Israel
Query!
State/province [95]
0
0
Kfar Saba
Query!
Country [96]
0
0
Israel
Query!
State/province [96]
0
0
Petah Tikva
Query!
Country [97]
0
0
Israel
Query!
State/province [97]
0
0
Safed
Query!
Country [98]
0
0
Israel
Query!
State/province [98]
0
0
Tel-Aviv
Query!
Country [99]
0
0
Italy
Query!
State/province [99]
0
0
Livorno
Query!
Country [100]
0
0
Italy
Query!
State/province [100]
0
0
Monza
Query!
Country [101]
0
0
Italy
Query!
State/province [101]
0
0
Novara
Query!
Country [102]
0
0
Italy
Query!
State/province [102]
0
0
Padova
Query!
Country [103]
0
0
Italy
Query!
State/province [103]
0
0
Palermo
Query!
Country [104]
0
0
Italy
Query!
State/province [104]
0
0
Parma
Query!
Country [105]
0
0
Italy
Query!
State/province [105]
0
0
Pisa
Query!
Country [106]
0
0
Italy
Query!
State/province [106]
0
0
Rome
Query!
Country [107]
0
0
Korea, Republic of
Query!
State/province [107]
0
0
Incheon
Query!
Country [108]
0
0
Korea, Republic of
Query!
State/province [108]
0
0
Seoul
Query!
Country [109]
0
0
Korea, Republic of
Query!
State/province [109]
0
0
Suwon-City
Query!
Country [110]
0
0
Mexico
Query!
State/province [110]
0
0
Guadalajara
Query!
Country [111]
0
0
Mexico
Query!
State/province [111]
0
0
Mexico City
Query!
Country [112]
0
0
Netherlands
Query!
State/province [112]
0
0
Amsterdam
Query!
Country [113]
0
0
Netherlands
Query!
State/province [113]
0
0
Arnhem
Query!
Country [114]
0
0
Netherlands
Query!
State/province [114]
0
0
Harderwijk
Query!
Country [115]
0
0
Netherlands
Query!
State/province [115]
0
0
S-Hertogenbosch
Query!
Country [116]
0
0
Netherlands
Query!
State/province [116]
0
0
Zwolle
Query!
Country [117]
0
0
New Zealand
Query!
State/province [117]
0
0
Grafton
Query!
Country [118]
0
0
New Zealand
Query!
State/province [118]
0
0
Wellington
Query!
Country [119]
0
0
Norway
Query!
State/province [119]
0
0
Oslo
Query!
Country [120]
0
0
Norway
Query!
State/province [120]
0
0
Tromsø
Query!
Country [121]
0
0
Poland
Query!
State/province [121]
0
0
Gdansk
Query!
Country [122]
0
0
Poland
Query!
State/province [122]
0
0
Gdynia
Query!
Country [123]
0
0
Poland
Query!
State/province [123]
0
0
Glucholazy
Query!
Country [124]
0
0
Poland
Query!
State/province [124]
0
0
Krakow
Query!
Country [125]
0
0
Poland
Query!
State/province [125]
0
0
Lodz
Query!
Country [126]
0
0
Poland
Query!
State/province [126]
0
0
Opole
Query!
Country [127]
0
0
Poland
Query!
State/province [127]
0
0
Otwock
Query!
Country [128]
0
0
Poland
Query!
State/province [128]
0
0
Poznan
Query!
Country [129]
0
0
Puerto Rico
Query!
State/province [129]
0
0
Bayamon
Query!
Country [130]
0
0
Romania
Query!
State/province [130]
0
0
Bucharest
Query!
Country [131]
0
0
Romania
Query!
State/province [131]
0
0
Cluj-Napoca
Query!
Country [132]
0
0
Romania
Query!
State/province [132]
0
0
Iasi
Query!
Country [133]
0
0
Russian Federation
Query!
State/province [133]
0
0
Moscow
Query!
Country [134]
0
0
Russian Federation
Query!
State/province [134]
0
0
Saint Petersburg
Query!
Country [135]
0
0
Russian Federation
Query!
State/province [135]
0
0
Stavropol
Query!
Country [136]
0
0
Spain
Query!
State/province [136]
0
0
Barcelona
Query!
Country [137]
0
0
Spain
Query!
State/province [137]
0
0
Girona
Query!
Country [138]
0
0
Spain
Query!
State/province [138]
0
0
Las Palmas De Gran Canaria
Query!
Country [139]
0
0
Spain
Query!
State/province [139]
0
0
Madrid
Query!
Country [140]
0
0
Spain
Query!
State/province [140]
0
0
Mataró
Query!
Country [141]
0
0
Spain
Query!
State/province [141]
0
0
Pamplona
Query!
Country [142]
0
0
Spain
Query!
State/province [142]
0
0
Pozuelo De Alarcon
Query!
Country [143]
0
0
Sweden
Query!
State/province [143]
0
0
Eskilstuna
Query!
Country [144]
0
0
Sweden
Query!
State/province [144]
0
0
Linkoping
Query!
Country [145]
0
0
Sweden
Query!
State/province [145]
0
0
Lund
Query!
Country [146]
0
0
Sweden
Query!
State/province [146]
0
0
Solna
Query!
Country [147]
0
0
Switzerland
Query!
State/province [147]
0
0
Basel
Query!
Country [148]
0
0
Switzerland
Query!
State/province [148]
0
0
Bern
Query!
Country [149]
0
0
Switzerland
Query!
State/province [149]
0
0
Fribourg
Query!
Country [150]
0
0
Switzerland
Query!
State/province [150]
0
0
Luzern
Query!
Country [151]
0
0
Switzerland
Query!
State/province [151]
0
0
Zurich
Query!
Country [152]
0
0
Taiwan
Query!
State/province [152]
0
0
Kaohsiung
Query!
Country [153]
0
0
Taiwan
Query!
State/province [153]
0
0
Kuei Shan Hsiang
Query!
Country [154]
0
0
Taiwan
Query!
State/province [154]
0
0
Neihu Taipei
Query!
Country [155]
0
0
Taiwan
Query!
State/province [155]
0
0
Niao Sung Hsiang
Query!
Country [156]
0
0
Taiwan
Query!
State/province [156]
0
0
Taichung
Query!
Country [157]
0
0
Taiwan
Query!
State/province [157]
0
0
Taipei
Query!
Country [158]
0
0
Turkey
Query!
State/province [158]
0
0
Ankara
Query!
Country [159]
0
0
Turkey
Query!
State/province [159]
0
0
Istanbul
Query!
Country [160]
0
0
Turkey
Query!
State/province [160]
0
0
Izmir
Query!
Country [161]
0
0
Turkey
Query!
State/province [161]
0
0
Kayseri
Query!
Country [162]
0
0
United Kingdom
Query!
State/province [162]
0
0
East Yorkshire
Query!
Country [163]
0
0
United Kingdom
Query!
State/province [163]
0
0
Greater London
Query!
Country [164]
0
0
United Kingdom
Query!
State/province [164]
0
0
Lancashire
Query!
Country [165]
0
0
United Kingdom
Query!
State/province [165]
0
0
Manchester
Query!
Country [166]
0
0
United Kingdom
Query!
State/province [166]
0
0
North Lincolnshire
Query!
Country [167]
0
0
United Kingdom
Query!
State/province [167]
0
0
Scotland
Query!
Country [168]
0
0
United Kingdom
Query!
State/province [168]
0
0
West Midlands
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Eli Lilly and Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of the study is to compare the survival of participants who receive chemotherapy
and ramucirumab versus chemotherapy alone as second line treatment for NSCLC after prior
first line platinum-based chemotherapy.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01168973
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9AM - 5PM Eastern time (UTC/GMT - 5 hours, EST)
Query!
Address
0
0
Eli Lilly and Company
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01168973
Download to PDF